- Home
- SKLZ vs AVTX Comparison
SKLZ vs AVTX Comparison
Compare SKLZ & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- AVTX
- Stock Information
- Founded
- SKLZ 2012
- AVTX 2011
- Country
- SKLZ United States
- AVTX United States
- Employees
- SKLZ N/A
- AVTX N/A
- Industry
- SKLZ EDP Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SKLZ Technology
- AVTX Health Care
- Exchange
- SKLZ Nasdaq
- AVTX Nasdaq
- Market Cap
- SKLZ 136.4M
- AVTX 118.6M
- IPO Year
- SKLZ N/A
- AVTX 2015
- Fundamental
- Price
- SKLZ $8.54
- AVTX $9.88
- Analyst Decision
- SKLZ Buy
- AVTX Strong Buy
- Analyst Count
- SKLZ 1
- AVTX 8
- Target Price
- SKLZ $14.00
- AVTX $31.00
- AVG Volume (30 Days)
- SKLZ 105.8K
- AVTX 338.8K
- Earning Date
- SKLZ 08-07-2025
- AVTX 08-07-2025
- Dividend Yield
- SKLZ N/A
- AVTX N/A
- EPS Growth
- SKLZ N/A
- AVTX N/A
- EPS
- SKLZ N/A
- AVTX N/A
- Revenue
- SKLZ $93,320,000.00
- AVTX $441,000.00
- Revenue This Year
- SKLZ $17.44
- AVTX N/A
- Revenue Next Year
- SKLZ $12.03
- AVTX N/A
- P/E Ratio
- SKLZ N/A
- AVTX N/A
- Revenue Growth
- SKLZ N/A
- AVTX N/A
- 52 Week Low
- SKLZ $3.54
- AVTX $3.39
- 52 Week High
- SKLZ $9.11
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SKLZ 58.33
- AVTX 76.24
- Support Level
- SKLZ $8.10
- AVTX $8.41
- Resistance Level
- SKLZ $9.11
- AVTX $9.80
- Average True Range (ATR)
- SKLZ 0.50
- AVTX 0.85
- MACD
- SKLZ 0.03
- AVTX -0.01
- Stochastic Oscillator
- SKLZ 77.29
- AVTX 87.52
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).